Compare TG Therapeutics Inc (TGTX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M). The key difference: TG Therapeutics Inc is far larger — about 22.4× YieldMax Universe Fund of Option Income ETFs's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| TGTX | YMAX | |
|---|---|---|
Market Cap | $8.16B | $364M |
Volume | 1,735,121 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $59.06 | $12.98 |
52-Week Low | $26.94 | $7.27 |
Typical Hold Time | 16 Days | 56 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
YMAX trades at $7.48, down 0.66% with a bearish technical outlook showing 18 sell signals versus 2 buy signals. The ETF faces fundamental challenges with declining NAV and concerns about distribution sustainability despite offering high yields. Recent news highlights weekly dividend distributions but also raises questions about the fund's structure and cost efficiency.
The outlook remains cautious due to persistent NAV erosion and structural concerns. While the high distribution yield attracts income investors, the fund's declining share price and potential for reverse splits present significant risks. Investors should weigh the attractive income against the potential for principal erosion in this complex ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
